Literature DB >> 28984009

MicroRNA-125b expression and intrahepatic metastasis are predictors for early recurrence after hepatocellular carcinoma resection.

Tomonari Shimagaki1,2, Tomoharu Yoshizumi1, Norifumi Harimoto1, Sachiyo Yoshio2, Yutaka Naito3, Yusuke Yamamoto3, Takahiro Ochiya3, Yoshihiro Yoshida1, Tatsuya Kanto2, Yoshihiko Maehara1.   

Abstract

AIM: Early hepatocellular carcinoma (HCC) recurrence after curative resection is a known poor prognostic factor. We aimed to identify microRNAs associated with recurrence after curative HCC resection.
METHODS: To identify risk factors for early recurrence and metastasis, 694 patients who underwent primary curative HCC resection were analyzed. We evaluated microRNA expression in cancerous and non-cancerous tissues by microarray and quantitative PCR analyses using 16 HCC samples. We defined patients who had a recurrence within 1 year of resection as the early recurrence (ER) group, patients who had a recurrence within 1-5 years as the late recurrence (LR) group, and patients who did not recur during the 5-year observation period as the no recurrence (NR) group. We examined the relationship between microRNA expression and clinical features.
RESULTS: Multivariate analysis revealed that α-fetoprotein >31 ng/mL, tumor size >4 cm, and intrahepatic metastasis (IM) were significant factors. Afterwards, microarray analyses revealed that microRNA (miR)-125b-5p and miR-148a-3p were significantly downregulated in recurrent cases. The ratio of miR-125b-5p expression in cancerous versus non-cancerous tissue (miR-125b ratio), but not miR-148a-3p, was significantly lower in the ER group. Early recurrence was associated with reduced overall survival compared with the LR and NR group. The miR-125b ratio was significantly lower in the ER group than in the LR and NR groups. Multivariate analysis showed that a low miR-125b ratio and IM were independently associated with ER and disease-free survival.
CONCLUSIONS: Assessing tissue miR-125b-5p expression and IM is useful for stratifying patients at risk of early HCC recurrence after curative resection.
© 2017 The Japan Society of Hepatology.

Entities:  

Keywords:  early recurrence; hepatocellular carcinoma; intrahepatic metastasis; microRNA-125b

Year:  2017        PMID: 28984009     DOI: 10.1111/hepr.12990

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  10 in total

1.  MicroRNA-6852 suppresses cell proliferation and invasion via targeting forkhead box J1 in gastric cancer.

Authors:  Hui Yu; Jing Zhang; Qu Wen; Yi Dai; Wanli Zhang; Fen Li; Juan Li
Journal:  Exp Ther Med       Date:  2018-08-02       Impact factor: 2.447

2.  Experience With Changing Etiology and Nontransplant Curative Treatment Modalities for Hepatocellular Carcinoma in a Real-Life Setting-A Retrospective Descriptive Analysis.

Authors:  Suneel Tohra; Ajay Duseja; Sunil Taneja; Naveen Kalra; Ujjwal Gorsi; Arunanshu Behera; Lileswar Kaman; Divya Dahiya; Srimanta Sahu; Balkrishan Sharma; Virendra Singh; Radha K Dhiman; Yogesh Chawla
Journal:  J Clin Exp Hepatol       Date:  2021-02-11

3.  Exosome-mediated miRNA delivery promotes liver cancer EMT and metastasis.

Authors:  Qu Lin; Chu-Ren Zhou; Ming-Jun Bai; Duo Zhu; Jun-Wei Chen; Hao-Fan Wang; Ming-An Li; Chun Wu; Zheng-Ran Li; Ming-Sheng Huang
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

4.  MTP18 overexpression contributes to tumor growth and metastasis and associates with poor survival in hepatocellular carcinoma.

Authors:  Yu Zhang; Hui Li; Hulin Chang; Lixue Du; Jun Hai; Xilin Geng; Xiang Yan
Journal:  Cell Death Dis       Date:  2018-09-20       Impact factor: 8.469

5.  Development of a Non-Coding-RNA-based EMT/CSC Inhibitory Nanomedicine for In Vivo Treatment and Monitoring of HCC.

Authors:  Ruomi Guo; Zhiqiang Wu; Jing Wang; Qingling Li; Shunli Shen; Weiwei Wang; Luyao Zhou; Wei Wang; Zhong Cao; Yu Guo
Journal:  Adv Sci (Weinh)       Date:  2019-03-07       Impact factor: 16.806

6.  Integrated nomogram based on five stage-related genes and TNM stage to predict 1-year recurrence in hepatocellular carcinoma.

Authors:  Haohan Liu; Yongcong Yan; Ruibing Chen; Mengdi Zhu; Jianhong Lin; Chuanchao He; Bingchao Shi; Kai Wen; Kai Mao; Zhiyu Xiao
Journal:  Cancer Cell Int       Date:  2020-04-29       Impact factor: 5.722

7.  A novel prognostic model for hepatocellular carcinoma based on 5 microRNAs related to vascular invasion.

Authors:  Wei Chen; Hao Wang; Tong Li; Te Liu; Wenjing Yang; Anli Jin; Lin Ding; Chunyan Zhang; Baishen Pan; Wei Guo; Beili Wang
Journal:  BMC Med Genomics       Date:  2022-02-24       Impact factor: 3.063

8.  Identification of long non-coding RNA ZFAS1 as a novel biomarker for diagnosis of HCC.

Authors:  Ping Luo; Chunzi Liang; Xianwei Zhang; Xuefang Liu; Yingchao Wang; Mengmeng Wu; Xiaobo Feng; Jiancheng Tu
Journal:  Biosci Rep       Date:  2018-07-18       Impact factor: 3.840

Review 9.  Role of microRNAs in the main molecular pathways of hepatocellular carcinoma.

Authors:  Francesco Vasuri; Michela Visani; Giorgia Acquaviva; Thomas Brand; Michelangelo Fiorentino; Annalisa Pession; Giovanni Tallini; Antonia D'Errico; Dario de Biase
Journal:  World J Gastroenterol       Date:  2018-07-07       Impact factor: 5.742

10.  In silico identification of EP400 and TIA1 as critical transcription factors involved in human hepatocellular carcinoma relapse.

Authors:  Weiguo Hong; Yan Hu; Zhenping Fan; Rong Gao; Ruichuang Yang; Jingfeng Bi; Jun Hou
Journal:  Oncol Lett       Date:  2019-12-02       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.